Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer

NCT00811369 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Fulvestrant + ZACTIMA
DRUG: Fulvestrant + Placebo

Sponsor

Ontario Clinical Oncology Group (OCOG)

Collaborators

[object Object]